Certificate Of Correction That Broadens Is Invalid
Client Alert | 1 min read | 04.09.07
In Central Admixture Pharmacy Services, Inc. v. Advanced Cardiac Solutions, P.c., (No. 2006-1307, April 3, 2007), the Federal Circuit vacates a finding of patent infringement involving a chemical solution used during heart surgery and remands for redetermination of infringement under the patent’s original claims, uncorrected by an invalid certificate of correction. Summary judgment that the patent is not invalid is, however, affirmed.
The Federal Circuit panel disagrees with the district court’s determination that a certificate of correction of the patent, changing the word “osmolarity” to the word “osmolality” was appropriate. “Osmolarity” is the amount of solute per liter of total solution (mOsmol/L), and “osmolality” the amount of solute per kilogram of solvent (mOsmol/kg). In the asserted claims, a solution having an “osmolarity . . . of between about 400-500 mOsmol” was initially claimed, but was by the certificate to read “osmolality”. Because of the change in the range, the accused solution is more likely to infringe the corrected claims.
Invalidating a certificate of correction for impermissible broadening of the claims, says the panel, requires proof that the corrected claims are broader than the original claims, and that the presence of the error in the original claims, or how to correct it, is not clearly evident to one of skill in the art. The panel reasons that in the original claims, the word “osmolarity” is spelled correctly and reads logically in the context of the sentence. And because the error corrected by the certificate was not clearly evident to one of skill in the art, the result of the correction was to broaden the claims.
Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 8 min read | 04.27.26
Client Alert | 5 min read | 04.27.26
Drift Protocol Exploit: Why “Social Trust” Is the Newest Cybersecurity Gap
Client Alert | 4 min read | 04.27.26
Gaming Addiction Litigation: Turner v. Epic Games & Roblox and What It Means for the Industry
